Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
| Market Cap | 3.65M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -2.96M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | -10.00% |
| Sales | 254.9k | PEG | - | EPS past 5Y | - | 200D Avg Chg | -2.00% |
| Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -52.00% |
| Recommedations | - | Quick Ratio | 0.05 | Shares Outstanding | 132.63M | 52W Low Chg | 68.00% |
| Insider Own | 14.68% | ROA | -126.92% | Shares Float | 112.79M | Beta | 0.17 |
| Inst Own | - | ROE | - | Shares Shorted/Prior | -/- | Price | 0.03 |
| Gross Margin | 56.36% | Profit Margin | - | Avg. Volume | 4,299 | Target Price | - |
| Oper. Margin | -1,307.86% | Earnings Date | May 9 | Volume | 1,000 | Change | -22.19% |
About AEQUUS PHARMACEUTICALS INC
Aequus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. The company markets ZIMED PF, a preservative-free bimatoprost ophthalmic solution. It also develops a range of prescription-free dry eye products under the OPTASE name; and REV-0100 for the treatment of stargardt disease. The company was incorporated in 2013 and is headquartered in Vancouver, Canada.
AEQUUS PHARMACEUTICALS INC News